Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) FCF Margin (2021 - 2025)

Tarsus Pharmaceuticals has reported FCF Margin over the past 5 years, most recently at 14.04% for Q4 2025.

  • Quarterly results put FCF Margin at 14.04% for Q4 2025, up 4755.0% from a year ago — trailing twelve months through Dec 2025 was 3.1% (up 4314.0% YoY), and the annual figure for FY2025 was 3.1%, up 4314.0%.
  • FCF Margin for Q4 2025 was 14.04% at Tarsus Pharmaceuticals, up from 12.72% in the prior quarter.
  • Over the last five years, FCF Margin for TARS hit a ceiling of 563.79% in Q3 2021 and a floor of 3667.16% in Q4 2021.
  • Median FCF Margin over the past 5 years was 34.39% (2021), compared with a mean of 512.59%.
  • Peak annual rise in FCF Margin hit 355865bps in 2022, while the deepest fall reached -280832bps in 2022.
  • Tarsus Pharmaceuticals' FCF Margin stood at 3667.16% in 2021, then surged by 97bps to 108.51% in 2022, then crashed by -177bps to 300.82% in 2023, then soared by 89bps to 33.51% in 2024, then soared by 142bps to 14.04% in 2025.
  • The last three reported values for FCF Margin were 14.04% (Q4 2025), 12.72% (Q3 2025), and 28.92% (Q2 2025) per Business Quant data.